{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:26:30Z","timestamp":1762298790405,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00277-018-3354-1","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T18:21:11Z","timestamp":1525371671000},"page":"2253-2255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1845-4786","authenticated-orcid":false,"given":"Junji","family":"Hiraga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiko","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"3354_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"3354_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, L\u00f3pez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379\u2013391","journal-title":"Lancet Oncol"},{"key":"3354_CR3","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, al-Ali KH, Neubauer A, D\u00f6lken G, Naumann R, Knauf W, Freund M, Rohrberg R, H\u00f6ffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Gr\u00fcnhagen U, East German Study Group Hematology and Oncology Study (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986\u20131992","journal-title":"J Clin Oncol"},{"key":"3354_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1532\/IJH97.07028","volume":"86","author":"A Tomita","year":"2007","unstructured":"Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, Kinoshita T, Naoe T (2007) Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 86:49\u201357","journal-title":"Int J Hematol"},{"key":"3354_CR5","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885\u20134893. \n                    https:\/\/doi.org\/10.1182\/blood-2008-08-175208","journal-title":"Blood"},{"key":"3354_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/PAS.0b013e3182759008","volume":"37","author":"AM Maeshima","year":"2013","unstructured":"Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37:563\u2013570. \n                    https:\/\/doi.org\/10.1097\/PAS.0b013e3182759008","journal-title":"Am J Surg Pathol"},{"key":"3354_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbrc.2009.09.059","volume":"390","author":"T Sugimoto","year":"2009","unstructured":"Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T (2009) Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of complex and not by DNA methylation. Biochem Biophys Res Commun 390:48\u201353. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.059","journal-title":"Biochem Biophys Res Commun"},{"key":"3354_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.exphem.2013.02.011","volume":"41","author":"R Rahme","year":"2013","unstructured":"Rahme R, Benayoun E, Pautas C et al (2013) Treatment with 5-azacytidine upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Exp Hematol 41:505\u2013507. \n                    https:\/\/doi.org\/10.1016\/j.exphem.2013.02.011","journal-title":"Exp Hematol"},{"key":"3354_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13256-016-0809-7","volume":"10","author":"Y Tsutsumi","year":"2016","unstructured":"Tsutsumi Y, Ohigashi H, Ito S, Shiratori S, Teshima T (2016) 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report. J Med Case Rep 10:27. \n                    https:\/\/doi.org\/10.1186\/s13256-016-0809-7","journal-title":"J Med Case Rep"},{"key":"3354_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3960\/jslrt.56.89","volume":"56","author":"A Tomita","year":"2016","unstructured":"Tomita A (2016) Genetic and epigenetic modulation of CD20 expression in B-cell malignancies: molecular mechanisms and significance to rituximab resistance. J Clin Exp Hematop 56:89\u201399","journal-title":"J Clin Exp Hematop"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:08:23Z","timestamp":1556824103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3354"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3354-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"18 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was obtained from the patient for publication when he was alive. This study was performed in conformity with the Declaration of Helsinki and was approved by our ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}